Close
Oct 16, 2026
Limited sector assessment from issuer-specific facts in Massive news. The financial score remains incomplete.
1.Share price
Daily closes, adjusted for stock splits. Price return excludes dividends. Hover or tap to explore.
2.Our verdict
Waiting for a better price
At least one of the average and median targets falls short of our required potential: at least 15% and four percentage points above the historical annual SPY reference.
Analyst price targets · 12 months
Published analyst targets, compared with our dated share price.
- Average target
- $45.68
- Price potential
- +16.5%
- Analysts
- 14
- Low–high range
- $39.82$61.90
- Historical SPY reference · 5 years
- +11.6%
- Average target versus SPY hurdle
- 4.9 pp
- Buy threshold below
- $37.53
3.Investment case at publication
Novo Nordisk’s obesity opportunity meets a tougher fight for patients
Wegovy and Ozempic anchor a powerful treatment franchise, but competition and U.S. pricing pressure put the spotlight on product differentiation and research execution.
Novo Nordisk’s strength is its established position in diabetes care and its range of obesity treatments. The central business question is whether research and product development can sustain that position as rivals compete more aggressively and realized prices come under pressure.
Novo Nordisk earns money by manufacturing and selling diabetes, obesity and rare-disease medicines.
Provider news describes tougher competition from Eli Lilly, pressure on U.S. prices and setbacks in experimental treatments.
Financial statements are unavailable, so current margins, cash generation and financing capacity cannot be verified.
4.Available company information
Recent provider news puts competitive pressure at the center of Novo Nordisk’s story. It describes disappointment with the clarity of near-term guidance at its Capital Markets Day, alongside pressure on realized U.S. prices. No reported quarterly statements are available to establish the latest quarter’s sales or earnings.
5.The business
Novo Nordisk makes and sells medicines for diabetes, obesity and rare diseases.
We like the depth of this treatment franchise. Novo brings an established diabetes-care business together with standout obesity products such as Wegovy. Its strongest opportunity is to build on that foundation with compelling new treatments and more choice between oral and injectable medicines.
Massive’s company description identifies the Denmark-based company as a leading provider of diabetes care, with human and modern insulins alongside its oral and injectable therapies. Its rare-disease business specializes in protein treatments for hemophilia and other disorders, giving it a distinct activity beyond diabetes and obesity.
6.Growth
Obesity medicines and next-generation treatment candidates are the main opportunities highlighted in provider news. Those reports also describe intensifying competition from Eli Lilly and heavy reliance on semaglutide, the medicine behind Ozempic and Wegovy. That concentration makes the performance of this treatment family especially important to the wider business.
7.Profitability
Pressure on realized U.S. prices matters because Novo can receive less revenue from the medicines it sells. Provider news identifies this as a business headwind, but reported costs and margins are unavailable. The effect on operating profitability cannot therefore be established.
8.Earnings
Reported earnings and earnings per share are unavailable. News commentary describes near-term earnings headwinds, but it does not provide a verified earnings bridge separating pricing, treatment volumes and spending. It should not be treated as a reported quarterly result.
9.Cash flow
Research is central to Novo’s opportunity, and provider news highlights its drug-development capabilities. However, operating cash flow, research spending and capital investment are unavailable. There is no basis to judge how much cash the business generates after investment or how it funds that spending.
10.Balance sheet
Cash balances, debt and other balance-sheet figures are unavailable. Novo’s established market position does not by itself establish financing strength, and no conclusion can be drawn about its capacity to support development spending or shareholder distributions.
11.Valuation
The current analyst targets and SPY comparison are shown in Our verdict.
View the current assessment12.What we are watching
Watch how Novo responds to Eli Lilly’s competing obesity treatments and whether pressure on realized U.S. prices persists. Research execution also matters: provider news reports setbacks involving CagriSema and the ZEUS trial. Clear clinical progress and evidence that new treatments can broaden the franchise would be meaningful business milestones.